COVID-19 vaccine effectiveness
(Randomized evidence)
Search studies
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04649151 ModernaTX Ali K, N Engl J Med, 2021 Full text Commentary |
RNA based vaccine |
mRNA-1273 |
Placebo |
RCTPhase 2-3 | Healthy adolescents in 26 centers in the USA | N= 3732 |
Some concerns Details |
|
|
NCT04796896 Moderna TX Anderson E, N Engl J Med , 2022 a Full text Commentary |
RNA based vaccine |
mRNA-1273 |
Placebo |
RCTPhase 2-3 | Children 2 to 5 years of age, including healthy and those with stable chronic diseases in 87 centres in USA (79 sites) and Canada (8 sites). | N= 4048 |
Some concerns Details |
|
|
NCT04796896 Moderna TX Anderson E, N Engl J Med, 2022 b Full text Commentary |
RNA based vaccine |
mRNA-1273 |
Placebo |
RCTPhase 2-3 | Children 6 to 23 months of age, including healthy and those with stable chronic diseases in 87 centres in USA (79 sites) and Canada (8 sites). | N= 2355 |
Some concerns Details |
|
|
NCT04796896 ModernaTX Creech CB, N Engl J Med, 2022 KidCOVE Full text Commentary |
RNA based vaccine |
mRNA-1273 (50 mcg D0/28) |
Placebo |
RCTPhase 2-3 | Children aged 6-11 years, healthy or with stable chronic conditions and no known recent history of COVID-19 infection, at 87 centers in Canada and USA. | N= 4016 |
Some concerns Details |
|
|
NCT04470427 ModernaTX El Sahly H, N Engl J Med, 2021 COVE Full text Full text Commentary Commentary |
RNA based vaccine |
mRNA-1273 100 mcg D1/28 |
Placebo D1/28 |
RCTPhase 3 | Healthy adults with no known history of SARS-CoV-2 infection in 99 centers in the US | N= 30415 |
Some concerns Details |
|
|
NCT04677660 ModernaTX Masuda T, Vaccine, 2022 a Full text Commentary |
RNA based vaccine |
mRNA-1273 |
Placebo |
RCTPhase 1-2 | Healthy adults aged ≥ 20 years with no known history/risk of SARS-CoV-2 infection at 2 centers in Japan. | N= 200 |
Some concerns Details |
|